These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20395744)

  • 21. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
    Rajagopal PS; Nielsen S; Olopade OI
    JAMA Netw Open; 2019 Aug; 2(8):e1910142. PubMed ID: 31434110
    [No Abstract]   [Full Text] [Related]  

  • 22. Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
    Manchanda R; Lieberman S; Gaba F; Lahad A; Levy-Lahad E
    Annu Rev Genomics Hum Genet; 2020 Aug; 21():373-412. PubMed ID: 32315550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA testing: ethics lessons for the new genetics.
    Sherwin S
    Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
    [No Abstract]   [Full Text] [Related]  

  • 24. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
    Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
    Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
    [No Abstract]   [Full Text] [Related]  

  • 26. Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.
    Levy-Lahad E
    Genet Med; 2009 Sep; 11(9):620-1. PubMed ID: 19690506
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
    Jacobs C; Pichert G; Harris J; Tucker K; Michie S
    Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
    Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
    Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Testing After Previous BRCA Testing: A Case Study.
    Ward M
    Clin J Oncol Nurs; 2016 Dec; 20(6):660-663. PubMed ID: 27857264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    Hull LE; Haas JS; Simon SR
    Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretest genetic counseling informs patients with BRCA mutation.
    Printz C
    Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
    [No Abstract]   [Full Text] [Related]  

  • 34. Management updates for women with a BRCA1 or BRCA2 mutation.
    Nusbaum R; Isaacs C
    Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families.
    Berzina D; Nakazawa-Miklasevica M; Zestkova J; Aksenoka K; Irmejs A; Gardovskis A; Kalniete D; Gardovskis J; Miklasevics E
    BMC Med Genet; 2013 Jun; 14():61. PubMed ID: 23767878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families.
    Sinilnikova OM; Mazoyer S; Bonnardel C; Lynch HT; Narod SA; Lenoir GM
    Fam Cancer; 2006; 5(1):15-20. PubMed ID: 16528604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial communication and cascade testing among relatives of BRCA population screening participants.
    Lieberman S; Lahad A; Tomer A; Koka S; BenUziyahu M; Raz A; Levy-Lahad E
    Genet Med; 2018 Nov; 20(11):1446-1454. PubMed ID: 29595811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.
    Kohut K; D'Mello L; Bancroft EK; Thomas S; Young MA; Myhill K; Shanley S; Briggs BH; Newman M; Saraf IM; Cox P; Scambler S; Wagman L; Wyndham MT; Eeles RA; Ferris M
    Fam Cancer; 2012 Mar; 11(1):107-13. PubMed ID: 22016143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unknown significance.
    Couzin-Frankel J
    Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.